Adam Lenkowsky, Executive Vice President and Chief Commercial Officer of Bristol Myers Squibb Co, filed a Form 4 on November 4, 2026, disclosing transactions dated November 3, 2026, involving the vesting of restricted stock units and the withholding of shares for tax purposes.

Key Highlights

  • RSU vesting: 7,522 restricted stock units vested on November 3, 2026, representing one-third of an award granted on November 3, 2025, acquired at $0 per share.
  • Tax withholding: 3,848 shares were withheld for payment of taxes upon vesting, at a price of $61.71 per share.
  • Direct ownership after transactions: Lenkowsky directly held 23,380 shares of Common Stock, $0.10 par value, following the reported transactions.
  • Indirect holdings: An additional 6,035.24 shares are held indirectly through the BMS Savings and Investment Program, and 3,022.1 shares are held indirectly by spouse.
  • Remaining derivative securities: 15,046 restricted stock units remain outstanding, with the next vesting date of November 3, 2028, according to the filing.
  • Issuer: Bristol Myers Squibb Co, trading on NYSE:BMY.

Lenkowsky RSU Vesting and Tax Withholding Details at Bristol Myers Squibb

According to the Form 4 filed with the SEC on November 4, 2026, Adam Lenkowsky, EVP and Chief Commercial Officer of Bristol Myers Squibb Co (NYSE:BMY), reported two transactions in Common Stock, $0.10 par value, both dated November 3, 2026. The first transaction, coded "M," reflects the acquisition of 7,522 shares upon the vesting of restricted stock units at a price of $0, described in the filing as representing "vesting of one-third of restricted stock units granted on November 3, 2025." Following this transaction, Lenkowsky's direct beneficial ownership stood at 27,228 shares.

The second transaction, coded "F," reflects the disposal of 3,848 shares at $61.71 per share. The filing states these were "shares withheld for payment of taxes upon vesting of awards," reducing Lenkowsky's direct holdings to 23,380 shares. In addition to his direct position, the filing reports indirect ownership of 6,035.24 shares through the BMS Savings and Investment Program, described as based on a recent 401(k) plan statement, and 3,022.1 shares held indirectly by his spouse.

In Table II, the filing discloses that 7,522 restricted stock units were converted under transaction code "M" on November 3, 2026. The filing notes that each restricted stock unit converts into one share of common stock upon vesting, and that "the restricted stock units vest in three equal annual installments beginning on November 3, 2026." Following the conversion, 15,046 restricted stock units remain directly held, with an expiration date of November 3, 2028. The Form 4 was signed by Amy Fallone as attorney-in-fact for Adam Lenkowsky.

What Was Disclosed

The filing reports the vesting of 7,522 restricted stock units and the withholding of 3,848 shares at $61.71 for taxes by Bristol Myers Squibb's Chief Commercial Officer on November 3, 2026, leaving 23,380 shares held directly and 15,046 RSUs remaining.